118 related articles for article (PubMed ID: 15273710)
21. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
22. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
24. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
[TBL] [Abstract][Full Text] [Related]
25. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
26. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
27. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
[TBL] [Abstract][Full Text] [Related]
28. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.
Peggs KS; Kayani I; Edwards N; Kottaridis P; Goldstone AH; Linch DC; Hough R; Morris EC; Fielding A; Chakraverty R; Thomson KJ; Mackinnon S
J Clin Oncol; 2011 Mar; 29(8):971-8. PubMed ID: 21282545
[TBL] [Abstract][Full Text] [Related]
29. Donor leukocyte infusions for multiple myeloma.
Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
[TBL] [Abstract][Full Text] [Related]
30. [Donor peripheral hematopoietic stem cells infusion for prophylaxis of relapse of high risk leukemia after allogeneic hematopoietic stem cell transplantation].
Liu DH; Huang XJ; Chen H; Xu LP; Liu KY; Han W; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):6-9. PubMed ID: 16732930
[TBL] [Abstract][Full Text] [Related]
31. Donor lymphocyte infusions: the long and winding road: how should it be traveled?
Tomblyn M; Lazarus HM
Bone Marrow Transplant; 2008 Nov; 42(9):569-79. PubMed ID: 18711351
[TBL] [Abstract][Full Text] [Related]
32. Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias.
Bunin N; Aplenc R; Grupp S; Pierson G; Monos D
Bone Marrow Transplant; 2006 Jan; 37(2):143-9. PubMed ID: 16284615
[TBL] [Abstract][Full Text] [Related]
33. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies.
Medina DJ; Gharibo M; Savage P; Cohler A; Kuriyan M; Balsara B; Anand M; Schaar D; Krimmel T; Saggiomo K; Manago J; Talty L; Dudek L; Grospe S; Rubin A; Strair RK
Leuk Res; 2008 Dec; 32(12):1842-8. PubMed ID: 18614230
[TBL] [Abstract][Full Text] [Related]
35. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
36. Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation.
Hartwig M; Weigel S; Bernig T; Bader P; Dölken R; Beck J
Pediatr Hematol Oncol; 2007 Mar; 24(2):137-40. PubMed ID: 17454780
[TBL] [Abstract][Full Text] [Related]
37. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism.
Colvin GA; Berz D; Ramanathan M; Winer ES; Fast L; Elfenbein GJ; Quesenberry PJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):421-31. PubMed ID: 19285629
[TBL] [Abstract][Full Text] [Related]
38. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
39. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
